Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction
Xiaoyan Liu, Zhe Li, Shuai Liu, Zhanghua Chen, Zhiyao Zhao, Yi-you Huang, Qingling Zhang, Jun Wang, Yinyi Shi, Yanhui Xu, Jing Sun, Huifang Xian, Rongli Fang, Fan Bai, Changxing Ou, Bei Xiong, Andrew M Lew, Jun Cui, Hui Huang, Jincun Zhao, Xuechuan Hong, Yuxia Zhang, Fulin Zhou, Hai-Bin Luo
doi: https://doi.org/10.1101/2020.02.27.20027557
Abstract
The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro. It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients.
*注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
